Clinical Evaluation of a Specific Enteral Diet for Diabetics
- Conditions
- HyperglycemiaDiabeticsMetabolic Syndrome
- Registration Number
- NCT01247714
- Lead Sponsor
- Vegenat, S.A.
- Brief Summary
The hypothesis of the proposed trials is that the regular intake of a specific diet designed for enteral nutrition of type 2 diabetic patients results into a better nutritional status. Thus, the aim of the study is to scientifically evaluate the healthy effects of the administration of an enteral complete diet for diabetic patients (T-Diet plus Diabet).
- Detailed Description
This new complete diet has been carefully formulated, and incorporates functional ingredients based on:
1. A good gastrointestinal and metabolic tolerance of the product.
2. Beneficial outcomes in the nutritional status.
3. A good control of the glycaemic response and the lipidic profile, allowing an improvement of metabolic syndrome and insulin resistance indicators and hunger-satiety regulation.
The experimental enteral product is a complete diet that includes, as carbohydrates, high-molecular maltodextrin, resistant maltodextrin, fructooligosaccharides and cellulose, and does not contain added fructose. Indeed, this product contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 43
- Diabetic Subjects older than 55 years.
- Male or female
- Requirement of total enteral nutrition (TEN) during at least 3 months.
- Under medical supervision.
- Voluntary informed consent for participation.
- Unstable clinical situation
- Fatal illness
- Patients treated with lipidic drugs
- Refusal to participate in the study or being enrolled in other clinical trials.
- Social or humanitarian reason
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Nutritional status and Glycaemia 9 months * Evaluation of the nutritional status of diabetic patients fed the T-Diet Plus Diabet NP in comparison with the reference and the control diet.
* Evaluation of glycaemia and glycosylated hemoglobin
- Secondary Outcome Measures
Name Time Method Biochemicals parameters measure 9 months * Confirmation of gastrointestinal tolerance of the product
* To assess changes in glycaemic response and lipidic profile in theses patients in relation with the diet, including parameters characteristic of metabolic syndrome, insulin resistace and hunger-satiety mechanism.
* To analyse changes of incretins and gastrointestinal peptides levels.
* To compare inflammatory and endothelial damage markers related with cardiovascular morbidity.
* Genotyping and gene expression analysis of genes related with diabetes and insulin resistance
Trial Locations
- Locations (1)
Department of Biochemistry and Molecular Biology II. University of Granada
🇪🇸Granada, Spain
Department of Biochemistry and Molecular Biology II. University of Granada🇪🇸Granada, Spain